Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy / K.S. Saini, C. Lanza, M. Romano, E. de Azambuja, J. Cortes, B. de las Heras, J. de Castro, M. Lamba Saini, S. Loibl, G. Curigliano, C. Twelves, M. Leone, M.M. Patnaik. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 123:5(2020), pp. 694-697. [10.1038/s41416-020-0948-x]
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
G. CuriglianoConceptualization
;
2020
Abstract
Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Saini BJC and Curigliano.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
273.1 kB
Formato
Adobe PDF
|
273.1 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
